Thierry Dervieux

Prometheus (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

34h-index3.9kcitations180works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(71), Microscopic Colitis(46), Acute Lymphoblastic Leukemia research(38), Biosimilars and Bioanalytical Methods(38), Systemic Lupus Erythematosus Research(33)

Publications180 total

Therapeutic drug monitoring of adalimumab in hidradenitis suppurativa: a prospective observational study
Frontiers in Immunology·2026Open Access
PRECISION-GUIDED DOSING OF INFLIXIMAB IN IBD: INSIGHTS FROM THE BAYESIAN ESTIMATE SUSTAINING TROUGH (BEST) STUDY
Gastroenterology·2026
PRECISION-GUIDED DOSING OF INFLIXIMAB IN IBD: INSIGHTS FROM THE BAYESIAN ESTIMATE SUSTAINING TROUGH (BEST) STUDY
Inflammatory Bowel Diseases·2026Open Access
DOP017 Unique serological signatures enable the diagnosis and stratification of Inflammatory Bowel Disease
Journal of Crohn s and Colitis·2026Open Access
Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn’s Disease
Inflammatory Bowel Diseases·2025Open Access
0190 Adalimumab therapeutic drug monitoring in hidradenitis suppurativa
Journal of Investigative Dermatology·2025
Impact of Precision-Guided Dosing on Clinical Decision-Making and Health Care Utilization in Inflammatory Bowel Disease: A Retrospective Pretest/Posttest Real-World Study
Crohn s & Colitis 360·2025Open Access
1301: INTEGRIN ALPHA V BETA 6 AUTOANTIBODIES ARE A NOVEL BIOMARKER FOR BOTH DIAGNOSED AND PRECLINICAL COLONIC CROHN’S DISEASE
Gastroenterology·2025
1303: AN INTEGRATIVE BLOOD-BASED RISK SCORE PREDICTS DEVELOPMENT OF CROHN’S DISEASE
Gastroenterology·2025
Tu1876: HIGHER VEDOLIZUMAB CLEARANCE ASSOCIATES WITH POOR THERAPEUTIC OUTCOMES DURING MAINTENANCE THERAPY OF VEDOLIZUMAB IN CROHN’S DISEASE
Gastroenterology·2025
Su1917: SEROPROTEOMIC TESTING CAN IDENTIFY CLINICALLY WELL CROHN’S DISEASE PATIENTS WITH ACTIVE ENDOSCOPIC DISEASE
Gastroenterology·2025
Su1925: SEROPROTEOMIC INDEX OF ENDOSCOPIC ACTIVITY ASSOCIATES WITH ENDOSCOPIC OUTCOMES IN A LONGITUDINAL COHORT OF ADULTS ULCERATIVE COLITIS PATIENTS
Gastroenterology·2025
Tu1878: REAL WORLD EVIDENCE OF SERUM ADALIMUMAB CLEARANCE AND CONCENTRATIONS IN ASSOCIATION WITH SEROPROTEOMIC INDEX OF ENDOSCOPIC ACTIVITY IN PEDIATRIC INFLAMMATORY BOWEL DISEASE
Gastroenterology·2025
408: BROAD LANDSCAPE OF ANTIMICROBIAL AND AUTOANTIBODY SIGNATURES REVEALS SELECTIVE REACTIVITY IN THE PRE-CLINICAL PHASE OF INFLAMMATORY BOWEL DISEASE
Gastroenterology·2025
Su1902: CLINICAL VALIDITY OF A SEROPROTEOMIC INDEX OF ENDOSCOPIC ACTIVITY IN PEDIATRIC CROHN’S DISEASE
Gastroenterology·2025
Tu1879: IMPACT OF PRECISION GUIDED DOSING, FORECASTED TROUGH INFLIXIMAB CONCENTRATIONS AND CLEARANCE ON TREATMENT DECISION AND OUTCOME IN INFLAMMATORY BOWEL DISEASE: INTERIM ANALYSIS OF THE BEST STUDY
Gastroenterology·2025
The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program
Pharmaceutics·2025Open Access
Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease
Pharmaceutics·2025· 3 citedOpen Access
ANTI-αVβ6 AUTOANTIBODIES ARE PRESENT IN COLONIC CROHN’S DISEASE AND ASSOCIATE WITH DISEASE ACTIVITY
Gastroenterology·2025
ANTI-αVβ6 AUTOANTIBODIES ARE PRESENT IN COLONIC CROHN’S DISEASE AND ASSOCIATE WITH DISEASE ACTIVITY
Inflammatory Bowel Diseases·2025· 1 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Joel M. Kremer(8), John Conklin(8), Mary V. Relling(6), Rosalind Ramsey‐Goldman(6), Tyler O’Malley(6), Roberta Vezza Alexander(6), Roselyne Boulieu(5), Ching‐Hon Pui(5), Chaim Putterman(5), Kenneth Kalunian(5), Katie Smith(4), Javier G. Blanco(4), Richard Furie(4), Jill P. Buyon(4), Arthur Weinstein(4), Puja Chitkara(4), Daniel E. Furst(3), Diana Orentas Lein(3), Daniel J. Wallace(3), Mathew J. Edick(3)